Researchers identify key immune checkpoint protein that operates within T cells

June 01, 2020

Columbus, Ohio - A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute (OSUCCC - James) has identified a protein within certain immune cells that is required for optimal immune responses to cancer.

The findings, reported in the journal Science Advances, also suggest that the protein might be useful for predicting which cancer patients are less likely to respond to the form of therapy called immune checkpoint blockade.

The protein is called PCBP1, or poly(C)-binding protein 1. The researchers found that PCBP1 helps shape immune responses by ensuring that adequate numbers of activated immune T cells differentiate into cytotoxic T cells, which kill cancer cells. At the same time, PCBP1 prevents the development of too many regulatory T cells, which do not kill cancer cells.

"Our findings suggest that PCBP1 is a global intracellular immune checkpoint, and that targeting it would offer a way to influence antitumor responses during immune therapy," says principal investigator Zihai Li, MD, PhD, a professor in the Division of Medical Oncology at Ohio State and director of the Pelotonia Institute for Immuno-Oncology (PIIO) at the OSUCCC - James. Li is also a member of the OSUCCC - James Translational Therapeutics Research Program.

"Immune checkpoint blockade therapy has revolutionized cancer treatment, especially in melanoma, non-small cell lung, and head and neck cancer," says first author Ephraim Abrokwa Ansa-Addo, PhD, an assistant professor in the Division of Medical Oncology and also a member of the Translational Therapeutics Research Program. "But we need better ways to identify which patients will benefit from the therapy. PCBP1 may help us do that."

PCBP1 belongs to a family of molecules called RNA binding protein. It controls gene expression when immune T cells differentiate into either regulatory T cells or into cytotoxic T cells, which carry out immune responses against infection and cancer. (Cytotoxic T cells are a type of effector T cell.)

In activated T cells, PCBP1 prevents cytotoxic T cells from converting to regulatory T cells, thereby promoting immune responses against tumors.

For this study, researchers used cell lines, tumor models, animal models, and models of diabetes and graft-vs-host disease to achieve a better understanding of the role of PCBP1 in T cells. Graft-vs-host disease is a condition in which a donor's T-cells (graft) view the patient's health cells (host) as a foreign and then attack and damage those normal cells.

Key findings include:"Overall, our data indicate that PCBP1 shapes tolerance and immunity by distinctively regulating cytotoxic T-cell versus regulatory T-cell differentiation, and that it could be a marker for response to immune checkpoint blockade therapy," Li says.
-end-
This research was supported by the National Institutes of Health (CA188419, AI070603, and CA186866) and the American Cancer Society.

Other researchers involved in this study were Brian Riesenberg, The Ohio State University; Supinya Iamsawat, Davis Borucki, Michelle H. Nelson, Dongjun Chung, Chrystal M. Paulos, Bei Liu, Xue-Zhong Yu, Jin Hyun Nam and Philip H. Howe, Medical University of South Carolina; Huai-Cheng Huang, National Taiwan University; and Caroline Philpott, National Institute of Diabetes and Digestive and Kidney Disease.

About the OSUCCC - James

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs sponsored by the NCI. As the cancer program's 356-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet® designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care.

Ohio State University Wexner Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.